Document Detail


Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
MedLine Citation:
PMID:  12777996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied a series of 100 primary colorectal adenocarcinomas by immunohistochemistry with the monoclonal antibody PAb1801, and single-stranded conformation polymorphism (PCR-SSCP, exons 4-8) followed by direct sequencing of shifted bands. p53 Nuclear staining was undetectable (score 0) in 29 of 100 cases. However, gene mutations were detected in 15 of these cases, with all of these mutations leading to abnormal proteins. p53 Nuclear staining was detectable and scored as less than 10% tumor cells positive in 15 of 100 cases but was still considered to be displaying a p53-negative phenotype because the cut-off value for positivity was 10% positive tumor cells. Nevertheless, TP53 gene mutations were detected in 2 of these cases. p53 Nuclear immunoreactivities were detectable and scored as more than 10% tumor cells positive in 56 cases, considered the p53-positive phenotype. TP53 gene mutations were identified in 51 of these 56 cases. These results reveal that immunohistochemical assessment does not predict TP53 mutation status in colorectal adenocarcinoma, mainly in cases displaying absence of nuclear staining. It is thus concluded that molecular profiling should be conducted in parallel with immunophenotyping when analyzing colorectal tumors for p53 status.
Authors:
Anna Colomer; Nadina Erill; Montse Verdú; Ruth Roman; August Vidal; Carlos Cordon-Cardo; Xavier Puig
Related Documents :
15662716 - Quantifying levels of p53 mutation in mouse skin tumors.
25287076 - Quantitative t1 and t2 mapping in recurrent glioblastomas under bevacizumab: earlier de...
9020896 - K-ras codon 12 and 61 point mutations in bromodeoxyuridine- and n-nitrosomethylurea-ind...
10849326 - Mxi1 is a potential cellular target of carcinogens and frequently mutated in experiment...
12172946 - Infantile gliosarcoma: a case and a review of the literature.
12216086 - Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expressi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry     Volume:  11     ISSN:  1541-2016     ISO Abbreviation:  Appl. Immunohistochem. Mol. Morphol.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-02     Completed Date:  2004-04-23     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  100888796     Medline TA:  Appl Immunohistochem Mol Morphol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  130-7     Citation Subset:  IM    
Affiliation:
BIOPAT, Grup Assistència, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / genetics
Adult
Aged
Aged, 80 and over
Colorectal Neoplasms / genetics*
DNA Mutational Analysis
Data Interpretation, Statistical
Exons
Female
Gene Frequency
Genes, p53 / genetics*
Genotype
Humans
Immunohistochemistry
Male
Middle Aged
Mutation*
Phenotype
Spain
Tumor Suppressor Protein p53 / analysis*,  genetics
Chemical
Reg. No./Substance:
0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zonula occludens-1 and Her-2/neu expression in invasive breast carcinoma.
Next Document:  p27 and cyclin E/D2 associations in testicular germ cell tumors: implications for tumorigenesis.